Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides

Journal of Applied Physiology

Volumn 88, Issue 5, 2000, Pages 1721-1729

  Ahmed, Tahir ^a,b   Ungo, Jaime ^a   Zhou, Min ^a   Campo, Carlos ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Heparin oligossacharides; Late phase reaction

Indexed keywords

CARBACHOL; HEPARIN DERIVATIVE; HISTAMINE; LEUKOTRIENE D4; LOW MOLECULAR WEIGHT HEPARIN; OLIGOSACCHARIDE;

ANIMAL EXPERIMENT; ARTICLE; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; BRONCHUS REACTIVITY; DRUG EFFECT; FEMALE; LUNG RESISTANCE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST;

EID: 0034087906     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.2000.88.5.1721     Document Type: Article

References (53)

1. Abraham WM, Sielczak WM, Wanner A, Perruchoud AP, Blinder L, Stevenson JS, Ahmed A, and Yerger LD. Cellular markers of inflammation in the airways of allergic sheep with and without allergen-induced late responders. Am Rev Respir Dis 138: 1565-1571, 1988.
2. Ahmed T, Abraham WM, and D'Brot J. Effects of inhaled heparin on immunologic and non-immunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis 145: 566-570, 1992.
3. Ahmed T, Campo C, Abraham MK, Molinari JF, Abraham WM, Ashkin D, Syriste T, Andersson LO, Svahn CM, and Ahmed T. Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness and mast cell degranulation by a non-anticoagulant heparin: comparison with a low-molecular weight heparin. Am J Respir Crit Care Med 155: 1848-1855, 1997.
4. Ahmed T, D'Brot J, Abraham WM, Lucio J, Mendelssohn R, Robinson MJ, Shakir S, and SanPedro B. Heterogeneity of allergic airway responses in sheep: differences in signal transduction? Am J Respir Crit Care Med 154: 843-849, 1996.
5. 2 receptors in airway reaction to histamine in conscious sheep. J Appl Physiol 49: 826-833, 1980.
6. Ahmed T, Garrigo J, and Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 329: 90-95, 1993.
7. 3-mediated mast cell degranulation? J Appl Physiol 76: 893-901, 1994.
8. Barzu T, Molho P, Tobelem G, Petitou M, and Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochimie 845: 196-203, 1985.
9. Bowler SD, Smith SM, and Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 147: 160-163, 1993.
10. Burgess WH and Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58: 575-606, 1989.
11. Campo C, Molinari JF, Ungo J, and Ahmed T. Molecular weight-dependent effects of "non-anticoagulant heparins" on antigen-induced bronchoconstriction and airway hyperresponsiveness. J Appl Physiol 86: 549-557, 1999.
12. Cartier A, Thompson NC, Frith PA, Roberts R, and Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 70: 170-177, 1982.
13. Castellot JJ Jr, Cochran DL, and Karnovsky MJ. Effect of heparin on vascular smooth muscle cells. 1. Cell metabolism. J Cell Physiol 124: 21-28, 1985.
14. Cifonelli JA. The relationship of molecular weight, and sulfate content and distribution to anticoagulant activity of heparin preparations. Carbohydr Res 37: 145-154, 1974.
15. Cockcroft DW and Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 79: 734-740, 1987.
16. D'Brot J, Abraham WM, and Ahmed T. Effect of heparin on immunologic and non-immunologic bronchoconstrictor responses in allergic sheep with and without late responses (Abstract). Am Rev Respir Dis 143: A540, 1991.
17. Diamant Z, Timmers MC, van der Veen H, Page CP, van der Meer FJ, and Sterk PJ. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 153: 1790-1795, 1996.
18. Dolowitz DA and Dougherty TF. The use of heparin as an anti-inflammatory agent. Laryngoscope 70: 873-884, 1960.
19. 2+ influx through receptor-mediated activation of nonspecific cation channels in mast cells. Proc Natl Acad Sci USA 90: 3068-3072, 1993.
20. 1 antitrypsin: evidence for a heparin-induced cleaved form of the inhibitor. Arch Biochem Biophys 347: 19-29, 1997.
21. Folkman J and Ingber DE. Angiogenesis: regulatory role of heparin and related molecules. In: Heparin, edited by Lane DA and Lindahl U. London: Arnold, 1989, p. 317-333.
22. Garrigo J, Danta I, and Ahmed T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med 153: 1702-1707, 1996.
23. 3H] heparin in isolated rat Kupffer cells. Biol Pharm Bull 19: 864-868, 1996.
24. Ishihara M, Takano R, Kanda T, Hayashi K, Hara S, Kikuchi H, and Yoshida K. Importance of 6-O-sulfate groups of glucosamine residues in heparin for activation of FGF-1 and FGF-2. J Biochem (Tokyo) 118: 1255-1260, 1995.
25. Jacques LB. Heparins-anionic polyelectrolyte drugs. Pharmacol Rev 31: 99-166, 1979.
26. Jones CA, Williams KA, Finlay-Jones JJ, and Hart PH. Interleukin 4 production by human amnion epithelial cells and regulation of its activity by glycosaminoglycan binding. Biol Reprod 52: 839-847, 1995.
27. Laghi Pasini F, Pasqui AL, Ceccatelli L, Capechhi PL, Orrico A, and DiPerri T. Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage. Thromb Res 35: 527-537, 1984.
28. Lantz M, Thysell H, Nilsson E, and Olsson I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 88: 2026-2031, 1991.
29. Laurent TC, Tengblad A, Thunberg L, Höök M, and Lindahl U. The molecular-weight-dependence of the anticoagulant activity of heparin. Biochem J 175: 691-701, 1978.
30. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR, and Naparstek Y. Inhibition of T-lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 20: 493-499, 1990.
31. Lindahl U. Biosynthesis of heparin and related polysaccharides. In: Heparin: Chemical and Biological Properties, Clinical Applications, edited by Lane DA and Lindahl U. Boca Raton, FL: CRC, 1989, p. 159-189.
32. Lindahl U, Bäckström G, Thunberg L, and Leder IG. Evidence for a 3-O-sulfated D-glucosamine residue in the anti-thrombin-binding sequence of heparin. Proc Natl Acad Sci USA 77: 6551-6555, 1980.
33. Linhardt RJ and Loganathan D. Heparin, heparinoids and heparin oligosaccharides: structure and biological activities. In: Biomimetic Polymers, edited by Gebelein CG. New York: Plenum, 1990, p. 135-173.
34. Lipscombe RJ, Nakhoul A, Sanderson CJ, and Coombe DR. Interleukin-5 binds to heparin/heparan sulfate. A model for an interaction with extracellular matrix. J Leukoc Biol 63: 342-350, 1998.
35. Liu MC, Hubbard WC, Proud D, Stealey BA, Galli SJ, Kagey-Sobotka A, Bleeker ER, and Lichtenstein LM. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator and permeability changes. Am Rev Respir Dis 144: 51-58, 1991.
36. Lortat-Jacob H, Baltzer F, and Grimaud JA. Heparin decreases the blood clearance of interferon-γ and increases its activity by limiting the processing of its carboxyl-terminal sequence. J Biol Chem 271: 16139-16143, 1996.
37. Martinez-Salas J, Mendelssohn R, Abraham WM, Hsiao B, and Ahmed T. Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular weight dependence. J Appl Physiol 84: 222-228, 1998.
38. Matzner Y, Marx G, Drexler R, and Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 52: 134-137, 1984.
39. 1. J Cell Physiol 152: 430-440, 1992.
40. Molinari JF, Campo C, Abraham WM, Martinez-Salas J, and Ahmed T. Inhibition of antigen-induced airway hyperresponsiveness by ultralow molecular weight heparin. Am J Respir Crit Care Med 157: 887-893, 1998.
41. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, and Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82: 3253-3258, 1993.
42. O'Byrne PM, Dolovich J, and Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 136: 740-751, 1987.
43. O'Donnel WJ, Rosenberg MA, Kelleher K, Drazen JM, and Israel E. Inhaled heparin does not protect asthmatics against antigen-induced bronchoconstriction (Abstract). Am Rev Respir Dis 145: A422, 1992.
44. Pelikan Z, Knottnerus I, and Johansson SA. Effects of cromolyn (DSCG), nedocromil (NDS) and budesonide (BSA) on the dual late asthmatic response (DLAR) administered before and after allergen challenge (Abstract). Euro J Allergy Clin Immunol 47, Suppl: 129, 1992.
45. 2-macroglobulin. Clin Exp Allergy 28: 616-624, 1998.
46. Redini F, Tixier J, Petitou M, Choay J, Robert L, and Hornebeck W. Inhibition of leukocyte elastase by heparin and its derivates. Biochem J 252: 515-519, 1988.
47. Schwartz LB and Bradford TR. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J Biol Chem 261: 7372-7379, 1986.
48. Schwartz LB, Riedel C, Caulfield JP, Wasserman SI, and Austen KF. Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J Immunol 126: 2071-2078, 1981.
49. Seeds EAM, Hanss J, and Page CP. The effect of heparin and related proteoglycans on allergen and PAF-induced eosinophil infiltration. J Lipid Mediators 7: 269-278, 1993.
50. Tones MA, Bootman MD, Higgins BF, Lane DA, Pay GF, and Lindahl U. The effect of heparin on the inositol 1,4,5-trisphosphate receptor in rat liver microsomes. Dependence on sulphate content and chain length. FEBS Lett 252: 105-108, 1989.
51. Weiler JM, Edens RE, Linhardt RJ, and Kapelanski DP. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 148: 3210-3215, 1992.
52. Wright TC Jr, Johnstone TV, Castellot JJ, and Karnovsky MJ. Inhibition of rat cervical epithelial cell growth by heparin and its reversal by EGF. J Cell Physiol 125: 499-506, 1985.
53. Ying QL, Kemme M, Saunders D, and Simon SR. Glycosaminoglycans regulate elastase inhibition by oxidized secretory leukoprotease inhibitor. Am J Physiol Lung Cell Mol Physiol 272: L533-L541, 1997.